These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 115632)

  • 1. [Endocrinological studies on Parkinson's disease (author's transl)].
    Yamamoto M; Kito S; Itoga E; Kishida T; Kamiya K
    Rinsho Shinkeigaku; 1979 Jul; 19(7):413-22. PubMed ID: 115632
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroendocrinological studies of Parkinson disease.
    Kito S; Itoga E; Yamamoto M
    Hiroshima J Med Sci; 1984 Sep; 33(3):323-9. PubMed ID: 6511457
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of hypoglycaemia, TRH and levodopa on plasma growth hormone, prolactin, thyrotropin and cortisol in Parkinson's disease before and during therapy.
    Vogel HP; Ketsche R
    J Neurol; 1986 Jun; 233(3):149-52. PubMed ID: 3088217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberoinfundibular dopaminergic function in Parkinson's disease.
    Franceschi M; Camerlingo M; Perego L; Bottacchi E; Truci G; Mamoli A
    Eur Neurol; 1988; 28(3):117-9. PubMed ID: 3133213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)].
    García de Yébenes J; Avila C; Bazán E; García E; Gervás J; Maseda C; Mena M; Muradas V; Ramos JA
    Med Clin (Barc); 1982 Apr; 78(7):259-64. PubMed ID: 7087591
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of levodopa on thyroid function and prolactin release. A study in patients with Parkinson's disease.
    Lavin PJ; Gawel MJ; Das PK; Alaghband-Zadeh J; Rose FC
    Arch Neurol; 1981 Dec; 38(12):759-60. PubMed ID: 6797388
    [No Abstract]   [Full Text] [Related]  

  • 7. [Bromocryptin effect on growth hormone and prolactin secretion after administration of thyrotropin-releasing hormone in patients with primary hypothyroidism and acromegaly (author's transl)].
    Felt V; Nedvídková J; Krejcík L; Hainer V
    Cas Lek Cesk; 1977 May; 116(19):591-4. PubMed ID: 406999
    [No Abstract]   [Full Text] [Related]  

  • 8. [The impact of surgical treatment on endocrinological status of pituitary adenomas associated with hyperprolactinemia (author's transl)].
    Sato O; Hotta H; Nakagawa T; Sohma F; Hasunuma M; Tsuchida H; Tanabe S; Kobayashi K; Inoue Y
    No Shinkei Geka; 1982 Jan; 10(1):55-62. PubMed ID: 6281676
    [No Abstract]   [Full Text] [Related]  

  • 9. [Nycterohemeral variations of growth hormone and prolactin in 6 Parkinson's sufferers treated with bromocriptine (author's transl)].
    Passouant P; Besset A; Descomps B; Bonardet A; Billiard M; Nègre C
    Nouv Presse Med; 1979 Oct; 8(40):3237-42. PubMed ID: 534183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal regulation of prolactin release in idiopathic Parkinson's disease.
    Lawton NF; MacDermot J
    J Neurol Neurosurg Psychiatry; 1980 Nov; 43(11):1012-5. PubMed ID: 6777462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neuroendocrine correlations in the pathogenesis and pathology of Parkinson disease].
    Pinessi L; Sabbatini F; De Mattei M; Gentile S
    Minerva Med; 1984 Nov; 75(42):2539-42. PubMed ID: 6096765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypothalamic dysfunction in Parkinson's disease patients.
    Otake K; Oiso Y; Mitsuma T; Hirooka Y; Adachi K
    Acta Med Hung; 1994; 50(1-2):3-13. PubMed ID: 7638039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inappropriate thyrotropin secretion. Part 1: tumoral (author's transl)].
    Hamon P; Baulieu JL; Doumith R; Jambart S; Turpin G
    Nouv Presse Med; 1981 Jun; 10(27):2285-8. PubMed ID: 6791127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissociation of growth hormone and prolactin secretion in Parkinson's disease following chronic L-dopa therapy.
    Malarkey WB; Cyrus J; Paulson GW
    J Clin Endocrinol Metab; 1974 Aug; 39(2):229-35. PubMed ID: 4371345
    [No Abstract]   [Full Text] [Related]  

  • 15. The thyrotropin--releasing hormone (TRH) stimulation of thyrotropin (TSH) and prolactin (PRL) in normal Thai subjects.
    Himathongkam T; Namking M; Pavasuthipaisit K; Supasri Y; Pitchayayothin N
    J Med Assoc Thai; 1980 Aug; 63(8):454-62. PubMed ID: 6776210
    [No Abstract]   [Full Text] [Related]  

  • 16. [Mortality in Parkinson's disease and its modification by levodopa (author's transl)].
    Schneider E; Fischer PA; Jacobi P; Kolb R
    Fortschr Neurol Psychiatr; 1981 May; 49(5):187-92. PubMed ID: 7239405
    [No Abstract]   [Full Text] [Related]  

  • 17. [Patients with Parkinson disease: functional analysis of dopamine receptors by bromocriptine- thyrotropin-releasing hormone test].
    Díaz F; Liberman C; Chariá P
    Rev Med Chil; 1991 Mar; 119(3):252-7. PubMed ID: 1842116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Follow up of 30 cases of prolactin -- or somatotropin -- secreting adenomas after trans-spenoidal surgery (author's transl)(proceedings)].
    Jaquet P; Grisoli F; Guibout M; Lissitzky JC
    Ann Endocrinol (Paris); 1976; 37(4):283-4. PubMed ID: 828840
    [No Abstract]   [Full Text] [Related]  

  • 19. [Thyrotropin-releasing factor (author's transl)].
    Adler G
    Postepy Biochem; 1977; 23(1):3-20. PubMed ID: 404635
    [No Abstract]   [Full Text] [Related]  

  • 20. [Thyrotropin, prolactin, and growth-hormone responses to thyrotropin-releasing hormone in healthy subjects over eighty years (author's transl)].
    Shigemasa C; Okamura Y; Yoshida A; Onoyama S; Watanabe K; Mashiba H; Abe K
    Nihon Ronen Igakkai Zasshi; 1981 Nov; 18(6):403-9. PubMed ID: 6803041
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.